Stay updated with breaking news from John Farley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(CTN News) - U.S. officials have approved the first long-acting drug designed to safeguard babies and toddlers from respiratory syncytial virus (RSV), a
The US Food and Drug Administration (FDA) on Tuesday approved a drug to prevent Respiratory Syncytial Virus (RSV) in children aged up to 24 months who remain vulnerable to severe disease.Developed by AstraZeneca and Sanofi, the drug Nirsevimab, ...
The Food and Drug Administration approved a new drug to protect babies and toddlers against respiratory syncytial virus on Monday.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made versio
The new monoclonal antibody treatment can prevent serious respiratory disease caused by the common virus in infants and vulnerable children up to age 2.